Core Viewpoint - Kangdelai (603987.SH) has introduced a strategic investor, Changsha Medical Investment Co., Ltd., to enhance its competitive position and valuation in the healthcare industry through a share transfer of 21.84 million shares, representing 5% of the total share capital [1][4]. Group 1: Share Transfer Details - Kangdelai's controlling shareholder, Kangdelai Group, will transfer 21.84 million shares to Changsha Medical Investment at a price of 10.81 yuan per share, which is a 16.24% premium over the market closing price on the announcement date, totaling approximately 236 million yuan [2][4]. - Following the transaction, Changsha Medical's stake in Kangdelai will increase from 1.45% to 6.45% [4][5]. Group 2: Financial Performance - In the first half of 2025, Kangdelai reported revenue of 1.125 billion yuan, a year-on-year increase of 0.17%, with a net profit of 125 million yuan, up 18.94% [2][9]. - The company's operating costs decreased by 3.37% to 757 million yuan, contributing to an improved gross margin of 32.66%, which is an increase of 2.47 percentage points year-on-year [10][9]. Group 3: Strategic Goals - The share transfer aims to deepen Kangdelai Group's strategic layout and promote collaborative synergies, enhancing market competitiveness and optimizing corporate governance [5][6]. - Kangdelai plans to leverage the strategic partnership to expand its presence in the consumer healthcare sector and improve its overall business structure [5][6]. Group 4: Industry Position and R&D - Kangdelai is one of the few companies in China with a complete medical puncture device industry chain, focusing on integrated manufacturing and regional operational advantages [8]. - In the first half of 2025, Kangdelai invested 51.67 million yuan in R&D, accounting for 4.59% of its revenue, and achieved significant product registrations and certifications [11].

长江商报消息 ●长江商报记者 徐佳 医疗器械上市公司康德莱（603987.SH）引入战略投资方。 9月2日晚间，康德莱披露股东权益变动，公司控股股东康德莱集团拟向长沙械字号医疗投资有限公司（以下简 称"长沙械字号"）转让所持公司股份2183.95万股，占公司总股本的5%。交易完成之后，长沙械字号的持股比例将 提升至6.45%。 长江商报记者注意到，长沙械字号是创业板医疗上市公司可孚医疗的控股股东。此次向长沙械字号转让康德莱股 权，康德莱集团意在通过战略协同完善医疗大健康产业布局，提升上市公司估值与整体竞争力，为后续资本运作 奠定基础。 数据显示，2024年和2025年上半年，长沙械字号的净利润分别为1.22亿元、8779.03万元。截至2025年6月末，长沙 械字号的资产总额7.49亿元、负债总额3.35亿元。 本次交易中，康德莱每股作价10.81元，较公告披露当日康德莱二级市场收盘价溢价16.24%，对应交易总价约为 2.36亿元。 上述消息发布之后，9月3日，康德莱股价盘中最高涨至10.23元/股，当日收涨1.51%，报9.44元/股。 作为国内少数拥有完整医用穿刺器械产业链的综合型企业之一，康德莱依托制 ...

数据显示，招商基金旗下1只基金位居康德莱十大流通股东。招商量化精选股票发起式A（001917）二 季度减持251.36万股，持有股数327.11万股，占流通股的比例为0.75%。根据测算，今日浮盈赚取约 150.47万元。 招商量化精选股票发起式A（001917）成立日期2016年3月15日，最新规模27.65亿。今年以来收益 37.35%，同类排名744/4223；近一年收益73.66%，同类排名928/3780；成立以来收益268.66%。 招商量化精选股票发起式A（001917）基金经理为王平。 9月1日，康德莱涨5.06%，截至发稿，报9.55元/股，成交1.94亿元，换手率4.76%，总市值41.71亿元。 资料显示，上海康德莱企业发展集团股份有限公司位于上海市嘉定区高潮路658号，成立日期1998年7月 1日，上市日期2016年11月21日，公司主营业务涉及从事医用穿刺针、医用输注器械、介入器械等医疗 器械的研发、生产、销售和服务。主营业务收入构成为：穿刺护理类63.43%，标本采集类13.96%，其 他类13.23%，医美类5.30%，穿刺介入类4.08%。 从康德莱十大流通股东角度 风险提示： ...

9月1日，康德莱涨5.06%，截至发稿，报9.55元/股，成交1.93亿元，换手率4.76%，总市值41.71亿元。 资料显示，上海康德莱企业发展集团股份有限公司位于上海市嘉定区高潮路658号，成立日期1998年7月 1日，上市日期2016年11月21日，公司主营业务涉及从事医用穿刺针、医用输注器械、介入器械等医疗 器械的研发、生产、销售和服务。主营业务收入构成为：穿刺护理类63.43%，标本采集类13.96%，其 他类13.23%，医美类5.30%，穿刺介入类4.08%。 从康德莱十大流通股东角度 数据显示，国寿安保基金旗下1只基金位居康德莱十大流通股东。国寿安保智慧生活股票A（001672） 二季度持有股数421万股，持股数量与上期相比不变，占流通股的比例为0.96%。根据测算，今日浮盈 赚取约193.66万元。 国寿安保智慧生活股票A（001672）成立日期2015年9月1日，最新规模18.28亿。今年以来收益 38.43%，同类排名687/4223；近一年收益86.88%，同类排名608/3780；成立以来收益225.05%。 国寿安保智慧生活股票A（001672）基金经理为张琦。 截至发稿，张琦累计 ...

Core Viewpoint - The article discusses the financial performance and market position of Kangdai, highlighting a decline in revenue and profit while emphasizing the company's efforts in product innovation and market adaptation [3][4][5]. Financial and Market Performance - In 2024, Kangdai reported total revenue of 2.261 billion yuan, a year-on-year decrease of 7.79% due to changes in the market environment affecting product sales [3][5]. - The net profit attributable to shareholders was 215 million yuan, down 6.75% year-on-year, although the fourth quarter saw a net profit of 50.29 million yuan, an increase of 13.73% compared to the previous year [5]. - The company's total expenses for sales, management, and finance amounted to 384 million yuan, accounting for 16.96% of revenue, a slight decrease of 0.17% year-on-year [5]. - The net cash flow from operating activities was 292 million yuan, down 33.47% year-on-year [5]. - Kangdai's asset-liability ratio was 29.86% in 2024, a decrease of 12.49% from 2023, indicating improved debt repayment capability [5]. Main Business and Business Model - Kangdai's primary business includes the research, production, sales, and service of medical devices such as medical puncture needles and infusion devices [3]. - The business model primarily focuses on self-branded product sales while also providing related medical device services [3]. Comprehensive Analysis - The overall market size of the medical device industry continues to grow, but competition is intensifying, particularly due to the normalization of centralized procurement [4]. - Despite revenue and profit declines, Kangdai has seen slight growth in its proprietary product business and is actively enhancing product quality and driving technological innovation [4]. About Kangdai - Established in 1987 and headquartered in Shanghai, Kangdai specializes in the research, production, and sales of disposable medical puncture devices [5]. - The company has been recognized as a "High-tech Enterprise" and has received support for its innovative projects, including the development of high-tech medical products [7]. Products and Technology - Kangdai's product line includes medical puncture needles, infusion devices, high polymer consumables, interventional consumables, and medical packaging, among others [7]. - The company employs advanced technology and equipment to ensure the highest quality of medical devices [7]. Market and Cooperation - Kangdai is adapting to changes in medical insurance policies and centralized procurement by employing a marketing model that combines agency distribution, delivery, and service [8]. - The company's products are sold domestically and exported to over 50 countries and regions, establishing long-term cooperative relationships [8].

报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2025年4月21日， 康德莱 发布了2024年年报。 # 财务与市场表现 # 主营业务与商业模式 康德莱的主要业务包括 医用穿刺针、医用输注器械等医疗器械的研发、生产、销售和服务 。其商业模式主要 以自有品牌产品销售为主，同时提供相关的医疗器械服务。2024年，公司营业收入为22.61亿元，同比下降 7.79%。这一下降主要源于市场环境的变化，导致公司产品销售受到一定影响。 # 综合分析 医疗器械行业整体市场规模持续增长，但市场竞争也日益激烈。尤其是在医疗器械集中带量采购常态化的背景 下，康德莱的市场份额和盈利能力受到一定挤压。尽管如此，康德莱通过调整经营策略、优化成本结构和推进 新产品上市等措施，试图稳住基本盘。 康德莱的核心驱动力在于其持续的研发投入和产品创新。 2024年，公司扣非净利润为2.11亿元，同比下降 5.44%。尽管面临营收和利润的下滑，但公司在自有产品业务上仍略有增长。此外，公司在医疗器械行业标 准制修订加速的背景下，积极提升产品质量，推动技术创新。 # 关于康德莱 营 ...